wo classes of proposals will be considered in response to this solicitation: Research Proposals describing collaborative research projects, and Data Sharing Proposals to enable sharing of data and other resources. Domestic and international projects will be considered. As detailed in the solicitation, international components of collaborative projects may be funded in parallel by the participating agencies. Specific CRCNS opportunities for parallel funding are available for bilateral US-German Research Proposals, US-German Data Sharing Proposals, US-French Research Proposals, US-French Data Sharing Proposals, US-Israeli Research Proposals, US-Israeli Data Sharing Proposals, US-Japanese Research Proposals, US-Japanese Data Sharing Proposals, US-Spanish Research Proposals, US-Spanish Data Sharing Proposals, and multilateral proposals involving the United States and two or more CRCNS partner countries (please see Section VIII of the solicitation for country-specific instructions and limitations).
The purpose of this program is to provide funding to states to enhance/expand their treatment service systems to increase capacity and provide accessible, effective, comprehensive, coordinated care, and evidence-based medication assisted treatment (MAT) and recovery support services to individuals with opioid use disorders seeking or receiving MAT. As a result of this program, SAMHSA seeks to: 1) increase the number of individuals receiving MAT services with pharmacotherapies approved by the FDA for the treatment of opioid use disorders; 2) increase the number of individuals receiving integrated care; and 3) decrease illicit drug use at 6-months follow-up. For the purpose of this RFA, integrated care is defined as the organized delivery and/or coordination of medical, behavioral or social and recovery support services provided to individual patients in order to produce better overall health outcomes for people that may have multiple healthcare needs. MAT is defined as the use of FDA-approved opioid agonist medications (e.g., methadone, buprenorphine products including buprenorphine/naloxone combination formulations and buprenorphine mono-product formulations) for the maintenance treatment of opioid use disorder and opioid antagonist medication (e.g., naltrexone products including extended-release and oral formulations) to prevent relapse to opioid use. MAT includes screening, assessment (which includes determination of severity of opioid use disorder, including presence of physical dependence and appropriateness for MAT) and case management. MAT is to be provided in combination with comprehensive substance use disorder treatment, including but not limited to: counseling, behavioral therapies and when needed pharmacotherapy for co-occurring alcohol use disorder. MAT is to be provided in a clinically driven, person-centered and individualized setting. Priority will be given to states (listed in Appendix V) that have not only demonstrated a high rate of primary treatme
NIDA is interested in research that addresses research gaps related to PrEP and its use among substance users, with the goals of improving PrEP management and implementation. Current US Public Health Service PrEP guidelines recommend PrEP for people who inject drugs (PWID) and mention alcohol and illicit drug use as potential concerns for clinical management. Only one clinical trial has evaluated PrEP among PWID and systematic data regarding the broader use of PrEP among substance users are limited. There is a need to better understand the effects of substance use on PrEP effectiveness and better inform PrEP implementation among substance users. More systematic data are needed regarding the impact of substance use on PrEP management and adherence, along with investigating potential unintended consequences of PrEP use that may be unique to substance users such as changes in harm reduction practices, as well as substance use as a contributor to health risk behaviors with consequences such as increased occurrence of STIs.
This FOA provides resources to support (a) pilot or feasibility studies of new or adapted interventions to prevent HIV infection among populations where substance use may be a contributing factor; (b) pilot or feasibility studies of new or adapted interventions to improve the care of HIV infection among populations where substance use is prevalent, including interventions that integrate treatment for substance use disorders and HIV infection; or (c) pilot or feasibility studies to increase the scale, uptake, delivery, and/or quality of HIV prevention or care interventions with established evidence of efficacy. Both primary and secondary prevention will be supported. The full range of substance use will be considered including problematic episodic use and substance use disorders, as well as a full range of substances and modes of administration. The most important consideration is that substance use may affect transmission directly as in the case of injection or may affect transmission risk behavior. Domestic and overseas populations will be considered, with particular attention to populations with disproportionate burden of HIV infection and those where HIV infection and/or drug use are emergent.
Despite significant scientific advancements made in substance use disorder research over the last century, the causes and consequences of drug use in later life remain poorly understood. The intent of this funding opportunity announcement is to support innovative research that examines aspects of marijuana and prescription opioid and benzodiazepine use in adults aged 50 and older. This FOA encourages research that examines the determinants of these types of drug use and/or characterizes the resulting neurobiological alterations, associated behaviors, and public health consequences. This initiative will focus on two distinct populations of older adults: individuals with earlier onset of drug use who are now entering this stage of adult development or individuals who initiate drug use after the age of 50. Applications are encouraged to utilize broad methodologies ranging from basic science, clinical, and epidemiological approaches. The insights gleaned from this initiative are critical to our understanding of the determinants of drug use in later life, as well as its consequences in the aging brain and on behavior. This knowledge may have the potential to identify risk factors and to guide clinical practices in older populations.
The purpose of this Funding Opportunity Announcement (FOA) is to accelerate research evaluating electronic cigarettes (e-cigarettes, electronic nicotine delivery systems, ENDS) as a potential means of reducing the risks associated with combustible tobacco use. This goal will be achieved by funding clinical studies that use the newly-developed NIDA Standard Research E-cigarette (SREC) to examine potential risks and benefits associated with e-cigarette use in current tobacco smokers. Ultimately, this FOA aims to evaluate whether e-cigarettes can reduce the risks associated with combustible tobacco use and to establish the NIDA SREC as a standard to which other e-cigarettes can be compared. Studies submitted to this FOA should examine the effects of the SREC on multiple behavioral and health biomarkers in current tobacco smokers and may include examination of whether e-cigarettes can reduce the negative health impacts of conventional tobacco use, and / or examine their effects on craving and dependence. Funding will be contingent upon the FDA Center for Tobacco Products (CTP) determination that the studies fall under their regulatory jurisdiction. Furthermore, funding will require that CTP accepts the use of the NIDA SREC as an Investigational Tobacco Product (ITP) in the proposed study, or determines that an ITP is not required. Studies funded by this FOA are expected to rapidly increase understanding of whether e-cigarettes reduce the risks associated with tobacco use. Additionally, these studies may provide significant data to inform e-cigarette public health policy decision-making.
This notice announces the opportunity to apply for funding under the Rural Communities Opioid Response Program - Rural Centers of Excellence on Substance Use Disorders (RCORP-RCOE). RCORP-RCOE is part of the RCORP initiative, which is a multiyear effort to reduce the morbidity and mortality of substance Use disorder (SUD), including opioid Use disorder (OUD), in rural communities at the highest risk for these conditions. RCORP-RCOE will provide up to three years of funding to support three Rural Centers of Excellence (Centers) on SUD. The purpose of RCORP-RCOE is to support the identification, translation, dissemination, and implementation of evidence-based programs and best practices "related to the treatment for and prevention of substance Use disorders within rural communities, with a focus on the current opioid crisis and developing methods to address future substance Use disorder epidemics."1 The Centers will engage in research to identify "science-based prevention, treatment, and other risk reduction interventions, including community-based approaches that may be replicable in other rural communities and associated professional training."2 After identifying rural-relevant interventions, the Centers will serve as a resource for "scientific and technical assistance to county and state health departments and other entities as identified seeking guidance on how to address the substance Use disorder challenges in their community."
NIDILRR proposes to fund two Disability and Rehabilitation Research Projects of three years each to conduct research on opioid use disorder among people with disabilities. Each grant will be funded up to $500,000. Topic of interest include: 1) Systematic review of existing literature on opioid-use disorder and people with disabilities; 2) Prevalence estimates and patterns of opioid use disorder treatment for people with disabilities; 3) Factors associated with increased risk for opioid use disorder; 4) Factors associated with improved access to treatment for opioid use disorder; 5) Interventions that contribute to improved outcomes; and 6) Effects of government policies and programs on access to treatment for people with disabilities who have opioid-use disorders.
This Funding Opportunity Announcement (FOA) is part of a trans-NIH initiative known as Collaborative Research on Addiction (CRAN). The goal of this FOA is to inspire and support research projects investigating the role of social media in risk behaviors associated with the use and abuse of alcohol, tobacco, and other drugs (hereafter referred to as "ATOD") and projects using social media to ameliorate such behaviors. Each research project proposed in response to this FOA must be focused on one of the two distinct areas: 1) observational research using social media interactions as surveillance tools to aid in the understanding of the epidemiology, risk factors, attitudes, and behaviors associated with ATOD use and addiction, or 2) intervention research measuring the reach, engagement, and behavioral and health impact of social media-based interventions for the screening, prevention, and treatment, of ATOD use and addiction. Original research preliminary data are not required but all projects are expected to be supported by a strong rationale that is based on integrating to the extent possible the available relevant information from various sources.
This Funding Opportunity Announcement (FOA) is part of a trans-NIH initiative known as Collaborative Research on Addiction (CRAN). The goal of this FOA is to inspire and support research projects investigating the role of social media in risk behaviors associated with the use and abuse of alcohol, tobacco, and other drugs (hereafter referred to as "ATOD") and projects using social media to ameliorate such behaviors. Each research project proposed in response to this FOA must be focused on one of the two distinct areas: 1) observational research using social media interactions as surveillance tools to aid in the understanding of the epidemiology, risk factors, attitudes, and behaviors associated with ATOD use and addiction, or 2) intervention research measuring the reach, engagement, and behavioral and health impact of social media-based interventions for the screening, prevention, and treatment of ATOD use and addiction.
To assist the Bureau of Land Management in managing Montezuma quail populations by evaluating Montezuma quail responses to common silviculture and rangeland practices in the Fort Stanton Snowy River National Conservation Area (NCA). (1) To describe spatial patterns and habitat use prior and after thinning projects (canopy cover reduced to a mosaic of 30% to 40% canopy cover) (2) controlled burns determine habitat use in relation to canopy cover (3) determine population characteristics (sex and age composition, survival rates, cause -specific mortality and density) of Montezuma quail in the NCA. Because few studies have been published on Montezuma quail using radio-telemetry, our knowledge on habitat use and life history is overly dependent on anecdotal observations. This study will be the first to document habitat use in relation to canopy cover, thinning projects and response to controlled burns. This project will address several conservation actions and monitoring recommendations for Montezuma quail. We will allow determination of current habitat use as well as provide needed information to construct management schemes to improve or maintain current Montezuma quail habitat. Ultimately, the understanding of the dynamics and ecology of Montezuma quail will aid in their management and the habitat they reside in.
This announcement solicits applications for the Rural Health Care Coordination Network Partnership Program (Care Coordination Program). The purpose of the Rural Health Care Coordination Network Partnership Program is to support the development of formal, mature rural health networks that focus on care coordination activities for the following chronic conditions: diabetes, congestive heart failure (CHF) and chronic obstructive pulmonary disease (COPD). Care coordination in the primary care practice involves deliberately organizing patient care activities and sharing information among all of the participants concerned with a patient¿s care to achieve safer and more effective care. Rural Americans are unhealthier, with higher rates of chronic illnesses, such as diabetes, CHF, and COPD and have higher rates of high-risk behaviors such as smoking, physical inactivity, and poor nutrition.[1],[2],[3],[4] These high-risk behaviors cause many of the illnesses, suffering and deaths due to chronic diseases and conditions.[5] The increasing prevalence of chronic diseases and the high cost of health care in the U.S. bring treatment of the ¿whole¿ person to the forefront, especially as there are often psychosocial (psychological and social) issues related to chronic diseases; for example, there is a link between diabetes and depression. In addition, more mental health problems are seen in the primary care setting than other health care settings; thus, integrating behavioral health care into primary care helps address both the physical and psychosocial aspects of health and wellness. Reviews and reports from the Agency for Healthcare Quality and Research (AHRQ) have shown a positive impact from integrating a team approach to care for a variety of disease conditions.[6] Health care coordination for people living with chronic conditions is vital to providing high quality care, especially in rural areas where access to health care is an issue. The main goal of care coordi
This FOA solicits development of innovative adaptations of existing technologies to enable their use for readily identifying, manipulating, or analyzing glycans and their biological binding partners. This may encompass the adaptation of commonly used laboratory-based or computational tools to enable their facile application to glycoscience for the first time, as well as the adaptation of tools presently used by specialists in glycoscience to make them significantly more straightforward and accessible for non-specialists. It is possible that a project might simplify a current specialized approach by migrating it to a more commonly used platform, developing automation for data acquisition and interpretation, or redesigning the present tool to make it easier to use. This announcement differs from the related FOA RFA- RM-16-022 which solicits new or more effective tools or technologies, thus representing an expansion of existing technologies.
Long-term misuse and chronic exposure to abused substances can produce widespread changes in brain structure and function. Although much progress has been made, additional research is still needed to identify the neurobiological changes that result from substance use, and how these changes contribute to substance use disorders. The overarching goals of the research areas described in this FOA are to understand the neurobiological mechanisms underlying substance use disorders, with special emphasis on identifying changes and neuroadaptations that occur during dependence, withdrawal, and relapse to chronic substance use. An understanding of the basic mechanisms underlying substance use disorders can help to identify targets for prevention and treatment interventions. Research utilizing basic, translational, or clinical approaches is appropriate.
The purpose of these cooperative agreements is to further IHS health program objectives in the AI/AN community with expanded outreach and education efforts for the MSPI and HIV/AIDS programs on a national scale and in the interest of improving Indian health care. This announcement includes two separate awards, each of which will be awarded as noted below. The purpose of the MSPI award is to further the goals of the national MSPI program. The MSPI is a national demonstration project aimed at addressing the dual problems of methamphetamine use and suicide in Indian Country. The MSPI supports an AI/AN community driven focus on the utilization and development of evidence-based and practice-based intervention models that promote a culturally appropriate prevention, treatment, and postvention approach to methamphetamine use and suicide. The six goals of the MSPI are to effectively prevent, reduce, or delay the use and/or spread of methamphetamine use; build on the foundation of prior methamphetamine and suicide prevention and treatment efforts in order to support the IHS, Tribes, and urban Indian health organizations in developing and implementing Tribal and/or culturally appropriate methamphetamine and suicide prevention and early intervention strategies; increasing access to methamphetamine and suicide prevention services; improving services for behavioral health issues associated with methamphetamine use and suicide prevention; promoting the development of new and promising services that are culturally and community relevant; and demonstrating efficacy and impact. The purpose of the HIV/AIDS award is to further the goals of the national HIV/AIDS program. HIV and AIDS are a critical and growing health issue within the AI/AN population. The IHS National HIV/AIDS Program seeks to avoid complacency and to increase awareness of the impact of HIV/AIDS on AI/ANs. All activities are part of the IHS's implementation plan to meet the three goals of the President's National HIV/A
The Division of Child, Adolescent, and Family Health (DCAFH) and the Division of Healthy Start and Perinatal Services (DHSPS), both parts of the Maternal and Child Health Bureau (MCHB) of the Health Resources and Services Administration (HRSA) in the U.S. Department of Health and Human Services (HHS) are accepting applications for the National Fetal, Infant, and Child Death Review Center (FICDRC or Center). Please read the entire FOA carefully before completing the application. The ultimate goal of fetal, infant and child death reviews is to prevent deaths of children through the use of information gained from systematic reviews that identify factors at the individual, environmental, clinical or systems levels that can be mitigated. Ideally by having this comprehensive review, factors associated with preventable deaths can be addressed. CDR and FIMR programs provide valuable information regarding fetal, infant and child deaths and provide insight into gaps in services, systems and modifiable risk factors not obtained from administrative surveillance systems. Information from these reviews can be used at the local, state and Federal levels to focus planning and policy development, quality improvement and health systems development, and to enhance efforts to develop and maintain risk reduction and prevention programs. This initiative will provide funds for a FICDRC to improve and strengthen state and local capacity to perform complete and accurate fetal and child death reviews including an estimated 1,200 CDR and 159 FIMR programs. Specifically, the Center will support the use of standardized data collection protocols and data elements to design prevention-oriented recommendations, and translate those recommendations into local, state and national program and policy development and quality improvement efforts. Through the delivery of data, training and technical support, the Center will assist State and community programs in understanding how CDR and FIMR can be
This notice solicits applications for the Rural Communities Opioid Response Program- Planning (RCORP-Planning). The purpose of RCORP-Planning is to support treatment for and prevention of substance use disorder, including opioid use disorder (OUD), in rural counties at the highest risk for substance use disorder. The overall goal of RCORP-Planning is to reduce the morbidity and mortality associated with opioid overdoses in high-risk rural communities by multi-sector consortiums (as defined in the "Eligibility Information" section) planning to strengthen their organizational and infrastructural capacity to address one or more of the following focus areas at the community, county, state, and/or regional levels: Prevention: reducing the occurrence of opioid use disorder among new and at-risk users, as well as fatal opioid-related overdoses, through activities such as community and provider education, and harm reduction measures including the strategic placement and use of overdose reversing devices, such as naloxone, and syringe services programs; (See page 20 for additional information) Treatment: implementing or expanding access to evidence-based practices for opioid addiction/OUD treatment, such as medication-assisted treatment (MAT) including developing strategies to eliminate or reduce treatment costs to uninsured and underinsured patients; and Recovery: expanding peer recovery and treatment options that help people start and stay in recovery. RCORP-Planning will support one (1) year of planning funding.
The National Institute on Drug Abuse (NIDA) intends to publish a series of Funding Opportunity Announcements (FOA) for Cooperative Agreements to solicit applications for a network of researchers collaborating across justice and community-based service settings to transform community-level responses to opioid misuse and opioid use disorder (OUD) in justice-involved populations. Opioid misuse and opioid use disorder consequences exist at the intersection of health and justice systems. Improving the capacity of the justice system to respond to opioid crisis with evidence-based approaches that include the use of medications for OUD requires strong partnerships between justice systems and healthcare as well as other community based organizations. Supporting the development of these relationships and novel models of justice-healthcare and otherncommunity collaboration is a critical target in addressing the current opioid crisis. NIDA is interested in launching a network of investigators who can rapidly conduct research to address the opioid crisis in justice settings. A variety of research methods will be used, including clinical trials, implementation science research, policy evaluations and/or modeling approaches. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and appropriate projects. This FOA is expected to use a multicomponent cooperative agreement mechanism. The FOA is expected to be published in October 2018 with an expected application due date in December 2018.
This Funding Opportunity Announcement encourages developmentally tailored research focused on adolescents and emerging adults as it relates to HIV prevention and treatment. Research is encouraged to incorporate recent advances in adolescent and young adult developmental research to optimize outcomes in HIV prevention and care research for this heterogeneous population.
PA-18-651 uses the R01 grant mechanism, PA-18-652 uses the R21 mechanism, while PA-18-653 uses the R34 mechanism. High risk/high payoff projects that lack preliminary data or utilize existing data may be most appropriate for the R21 mechanism. Applicants with preliminary data and/or planning to include longitudinal analysis may wish to apply using the R01 mechanism. Applicants wanting to develop and pilot test an intervention may wish to apply using the R34 mechanism. Also listed under R21
This Funding Opportunity Announcement encourages developmentally tailored research focused on adolescents and emerging adults as it relates to HIV prevention and treatment. Research is encouraged to incorporate recent advances in adolescent and young adult developmental research to optimize outcomes in HIV prevention and care research for this heterogeneous population. PA-FY-NNN uses the R01 grant mechanism, PA-FY-NNN uses the R21 mechanism, while PA-FY-NNN uses the R34 mechanism. High risk/high payoff projects that lack preliminary data or utilize existing data may be most appropriate for the R21 mechanism. Applicants with preliminary data and/or planning to include longitudinal analysis may wish to apply using the R01 mechanism. Applicants wanting to develop and pilot test an intervention may wish to apply using the R34 mechanism.
